April 3, 2017
Two new e-tailers for InnovaDerma’s products
InnovaDerma, a UK developer of life sciences, beauty and personal care products has secured new e-tailer distribution deals.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
April 3, 2017
Affimer technology in Industry-standard immunogenicity study using human samples
Avacta Group said on Monday that the first major immunogenicity study of Affimer technology using human ex-vivo samples was successful with a range of Affimer proteins shown to have low immunogenicity comparable with the marketed antibody Avastin.
April 3, 2017
Verona Pharma in managerial changes
Verona Pharma’s non-executive director Patrick Humphrey has decided to retire from the Board, effective April 15, 2017. The company said it doesn’t plan replacing him.
March 31, 2017
Pharmacy chain works to help curb opioid epidemic
The drugstore chain Walgreens is taking a three-pronged approach to combat the public health crisis stemming from prescription opioids, according to a team of pharmacists and other clinicians from the company.
March 31, 2017
FDA warnes African Viagra’s possible harmful ingredient
The Food and Drug Administration (FDA) has advised consumers not to purchase or use African Viagra, a product promoted for sexual enhancement.
March 31, 2017
AstraZeneca wins FDA’s full approval for its lung cancer drug
U.S. Food and Drug Administration (FDA) has granted regular approval to AstraZeneca’s osimertinib (Tagrisso), for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
March 31, 2017
CARB-X funds Tetraphase Pharmaceuticals antibiotic research with $4M
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance, will fund research of Tetraphase Pharmaceuticals’s pipeline candidate TP-6076, a novel, synthetic, fluorocycline antibiotic candidate with $4 million.
March 31, 2017
DBV, HUG and BioNet report results from Phase I study of pertussis vaccine
DBV Technologies, the Geneva University Hospitals (HUG) and BioNet-Asia have announced results from a Phase I trial assessing Viaskin rPT`s ability to boost immunity against pertussis by epicutaneously administering two doses of BioNet`s recombinant pertussis toxin.
March 31, 2017
Canadian cannabis company Invictus MD starts trading on TSX
Invictus MD Strategies Corp.,Canada’s cannabis company, said Thursday it will move its shares from the Canadian Securities Exchange and be listed on TSX Venture Exchange, where it starts trading on March 31, 2017.
March 31, 2017
J&J expect to close successful $30 billion Actelion tender offer in second quarter
Johnson & Johnson said its $30 billion tender offer for Swiss biotechnology company Actelion was successful, with the price of the offer being 280 per share for Actelion.